Literature DB >> 21819189

Epilepsy after subarachnoid hemorrhage: the frequency of seizures after clip occlusion or coil embolization of a ruptured cerebral aneurysm: results from the International Subarachnoid Aneurysm Trial.

Yvonne Hart1, Mary Sneade, Jacqueline Birks, Joan Rischmiller, Richard Kerr, Andrew Molyneux.   

Abstract

OBJECT: The aim of this study was to determine the probability of seizures after treatment of a ruptured cerebral aneurysm by clip occlusion and coil embolization, and to identify the risks and predictors of seizures over the short- and long-term follow-up period.
METHODS: The study population included 2143 patients with ruptured intracranial aneurysms who were enrolled in 43 centers and randomly assigned to clip application or coil placement. Those patients suffering a seizure were identified prospectively at various time points after randomization, as follows: before treatment; after treatment and before discharge; after discharge to 1 year; and annually thereafter.
RESULTS: Two hundred thirty-five (10.9%) of the 2143 patients suffered a seizure after randomization; 89 (8.3%) of 1073 and 146 (13.6%) of 1070 in the endovascular and neurosurgical allocations, respectively (p = 0.014). In 19 patients the seizure was associated with a rehemorrhage. Of those patients who underwent coil placement alone, without additional procedures, 52 suffered a seizure, and in the group with clip occlusion alone, 91 patients suffered a seizure. The risk of a seizure after discharge in the endovascular group was 3.3% at 1 year and 6.4% at 5 years. In the neurosurgical group it was 5.2% at 1 year and 9.6% at 5 years. The risk of seizure was significantly greater in the neurosurgical group at both 2 years and at up to 14 years (p = 0.005 and p = 0.013, respectively). The significant predictors of increased risk were as follows: neurosurgical treatment allocation, hazard ratio (HR) 1.64 (95% CI 1.19-2.26); younger age, HR 1.54 (95% CI 1.14-2.13); Fisher grade > 1 on CT scans, HR 1.34 (95% CI 0.62-2.87); delayed ischemic neurological deficit due to vasospasm, HR 2.10 (95% CI 1.49-2.94); and thromboembolic complication, HR 5.08 (95% CI 3.00-8.61). A middle cerebral artery (MCA) aneurysm location was also a significant predictor of increased risk in both groups; the HR was 2.23 (95% CI 1.57-3.17), with the probability of seizure at 6.1% and 11.5% at 1 year in the endovascular and neurosurgery groups, respectively.
CONCLUSIONS: The risk of seizures after coil embolization is significantly lower than that after clip occlusion. An MCA aneurysm location increased the risk of seizures in both groups.

Entities:  

Mesh:

Year:  2011        PMID: 21819189     DOI: 10.3171/2011.6.JNS101836

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.115


  10 in total

Review 1.  Subarachnoid haemorrhage (spontaneous aneurysmal).

Authors:  Kieron Sweeney; Nicholas Silver; Mohsen Javadpour
Journal:  BMJ Clin Evid       Date:  2016-03-17

2.  Frequency of non-convulsive seizures and non-convulsive status epilepticus in subarachnoid hemorrhage patients in need of controlled ventilation and sedation.

Authors:  Cecilia Lindgren; Erik Nordh; Silvana Naredi; Magnus Olivecrona
Journal:  Neurocrit Care       Date:  2012-12       Impact factor: 3.210

3.  Incidence and risk factors of epilepsy following brain arteriovenous malformation rupture in adult patients.

Authors:  Gonzague Guillaumet; Eimad Shotar; Frédéric Clarençon; Nader-Antoine Sourour; Kevin Premat; Stéphanie Lenck; Sophie Dupont; Alice Jacquens; Vincent Degos; Tom Boeken; Aurélien Nouet; Alexandre Carpentier; Bertrand Mathon
Journal:  J Neurol       Date:  2022-07-22       Impact factor: 6.682

4.  Endovascular treatment of 300 consecutive middle cerebral artery aneurysms: clinical and radiologic outcomes.

Authors:  A M Mortimer; M D Bradley; P Mews; A J Molyneux; S A Renowden
Journal:  AJNR Am J Neuroradiol       Date:  2013-11-14       Impact factor: 3.825

Review 5.  Nonconvulsive status epilepticus in adults - insights into the invisible.

Authors:  Raoul Sutter; Saskia Semmlack; Peter W Kaplan
Journal:  Nat Rev Neurol       Date:  2016-04-11       Impact factor: 42.937

6.  High risk for seizures following subarachnoid hemorrhage regardless of referral bias.

Authors:  Kathryn L O'Connor; M Brandon Westover; Michael T Phillips; Nicolae A Iftimia; Deidre A Buckley; Christopher S Ogilvy; Mouhsin M Shafi; Eric S Rosenthal
Journal:  Neurocrit Care       Date:  2014-12       Impact factor: 3.210

Review 7.  Korean Clinical Practice Guidelines for Aneurysmal Subarachnoid Hemorrhage.

Authors:  Won-Sang Cho; Jeong Eun Kim; Sukh Que Park; Jun Kyeung Ko; Dae-Won Kim; Jung Cheol Park; Je Young Yeon; Seung Young Chung; Joonho Chung; Sung-Pil Joo; Gyojun Hwang; Deog Young Kim; Won Hyuk Chang; Kyu-Sun Choi; Sung Ho Lee; Seung Hun Sheen; Hyun-Seung Kang; Byung Moon Kim; Hee-Joon Bae; Chang Wan Oh; Hyeon Seon Park
Journal:  J Korean Neurosurg Soc       Date:  2018-02-28

8.  Postoperative de novo epilepsy after craniotomy: a nationwide register-based cohort study.

Authors:  Laura Giraldi; Jørgen Vinsløv Hansen; Jan Wohlfahrt; Kåre Fugleholm; Mads Melbye; Tina Nørgaard Munch
Journal:  J Neurol Neurosurg Psychiatry       Date:  2021-11-29       Impact factor: 10.154

9.  Seizure prophylaxis following aneurysmal subarachnoid haemorrhage (SPSAH): study protocol for a multicentre randomised placebo-controlled trial of short-term sodium valproate prophylaxis in patients with acute subarachnoid haemorrhage.

Authors:  Yuqi Chen; Mei Fang; Pei Wu; Zhiyi Xie; Honggang Wu; Qiaowei Wu; Shancai Xu; Yuchen Li; Bowen Sun; Bo Pang; Niandong Zheng; Jianmin Zhang; Xin Hu; Chao You
Journal:  BMJ Open       Date:  2022-05-04       Impact factor: 2.692

10.  Effects of Prophylactic Antiepileptic Drugs on Clinical Outcomes in Patients with a Good Clinical Grade Suffering from Aneurysmal Subarachnoid Hemorrhage.

Authors:  Seon Jin Yoon; Jin-Yang Joo; Yong Bae Kim; Chang-Ki Hong; Joonho Chung
Journal:  J Cerebrovasc Endovasc Neurosurg       Date:  2015-09-30
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.